Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Fuji
Deloitte
Farmers Insurance
Daiichi Sankyo
US Army
Covington

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOLTERODINE TARTRATE

« Back to Dashboard

Clinical Trials for Tolterodine Tartrate

Trial ID Title Status Sponsor Phase Summary
NCT00143377 Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB Completed Pfizer Phase 4 The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.
NCT00293839 Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder Completed Alza Corporation, DE, USA Phase 3 The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.
NCT00454740 Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder Completed Astellas Pharma Inc Phase 3 To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
NCT00768521 A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) Completed Merck Sharp & Dohme Corp. Phase 1 This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tolterodine Tartrate

Condition Name

Condition Name for Tolterodine Tartrate
Intervention Trials
Overactive Bladder 4
Urinary Incontinence 2
Lower Urinary Tract Symptoms 1
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tolterodine Tartrate
Intervention Trials
Urinary Bladder, Overactive 7
Urinary Incontinence 3
Enuresis 2
Lower Urinary Tract Symptoms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tolterodine Tartrate

Trials by Country

Trials by Country for Tolterodine Tartrate
Location Trials
United States 35
China 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tolterodine Tartrate
Location Trials
Georgia 2
California 2
Texas 2
Missouri 1
Nevada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tolterodine Tartrate

Clinical Trial Phase

Clinical Trial Phase for Tolterodine Tartrate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tolterodine Tartrate
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tolterodine Tartrate

Sponsor Name

Sponsor Name for Tolterodine Tartrate
Sponsor Trials
Merck Sharp & Dohme Corp. 1
Federal University of São Paulo 1
Astellas Pharma Inc 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tolterodine Tartrate
Sponsor Trials
Industry 7
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Cantor Fitzgerald
Mallinckrodt
Merck
Daiichi Sankyo
Argus Health
Moodys
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.